Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
01:31pm, Thursday, 30'th May 2024
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
3 Stocks That Could Be Easy Wealth Builders
09:31am, Thursday, 30'th May 2024
Amazon combines strong e-commerce fundamentals with the explosive growth potential of AWS cloud computing. Visa leads the digital payments industry while exploring cutting-edge crypto solutions.
Sarepta Therapeutics Set to Join S&P MidCap 400
05:48pm, Wednesday, 29'th May 2024
NEW YORK , May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monda
Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript)
04:36pm, Wednesday, 29'th May 2024
Johnson & Johnson (NYSE:JNJ ) Bernstein's 40th Annual Strategic Decisions Conference Call May 29, 2024 1:30 PM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Conference C
Are You Looking for a High-Growth Dividend Stock?
12:46pm, Wednesday, 29'th May 2024
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
10:05am, Wednesday, 29'th May 2024
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
09:26am, Wednesday, 29'th May 2024
J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.
J&J's treatment for depression succeeds in late stage study
08:12am, Wednesday, 29'th May 2024
Johnson & Johnson said on Wednesday its experimental therapy, seltorexant, met all main and secondary goals in a late-stage study evaluating it in patients with major depressive disorder (MDD) and ins
HealthTech Heroes: 3 Medical Technology Stocks to Buy Before They Boom
02:15pm, Tuesday, 28'th May 2024
While the biotechnology sector may receive most of the attention under the broad healthcare umbrella, investors ought to spare some love for medical technology stocks. The enterprises undergirding the
Trade Tracker: Stephanie Link sells Johnson & Johnson
01:45pm, Tuesday, 28'th May 2024
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to break down her latest trades.
J&J acquires rights to skin disorder drug for $1.25 bln
07:55am, Tuesday, 28'th May 2024
Johnson & Johnson said on Tuesday it had agreed to acquire the rights to an experimental skin disorder treatment from privately held Numab Therapeutics for about $1.25 billion.
Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
07:30am, Tuesday, 28'th May 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology company advancing
Going Beyond Morningstar's 10 Best Dividend Stocks List
08:55pm, Monday, 27'th May 2024
Morningstar published their 10 Best Dividend Stocks, which are undervalued blue-chip stocks with reliable dividends. The article analyzes the valuation and estimated future total return of each stock,
7 Dividend Stocks That Could Soar After Q1 Earnings Reports
06:00am, Monday, 27'th May 2024
Dividend investment can make you wealthy but you need to pick the right stocks. Whether you are just beginning your investment journey or are a professional at it, there is nothing better than receivi
